News | February 17, 2025
Sanofi updates on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
No safety signals related to the vaccine candidate were identified
No safety signals related to the vaccine candidate were identified
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status for metastatic breast cancer patients.
If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population
Lonza to develop spray-dried formulations for an intranasally-delivered biologic for Iconovo at its Center of Excellence for bioavailability enhancement and inhaled delivery in Bend (US)
Afrezza, developed by MannKind Corporation in the USA, offers a needle-free, rapid-acting insulin option for diabetes management
First and only PARP inhibitor to improve overall survival in early breast cancer
This agreement reinforces Lubrizol’s commitment to Make-In-India and broadens a previously committed US$ 350 million investment to support local manufacturing
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
To set a new standard in oncology, offering highly targeted radiation therapy that improves treatment precision, and accelerates recovery for cancer patients
Subscribe To Our Newsletter & Stay Updated
